Thermo Fisher Scientific has raised $4.8 billion through a new bond offering, marking a significant step in financing its planned acquisition of Clario Holdings, Inc. The company issued four series of senior notes with maturities ranging from 2031 to 2046, offering investors a mix of fixed interest rates and staggered maturities. This debt issuance is part of Thermo Fisher’s broader strategy to fund the Clario deal and potentially support other corporate needs.
This move reflects Thermo Fisher’s approach to capital management as it pursues growth through acquisition, while maintaining flexibility in its use of proceeds and managing its debt profile.
Key details of the bond offering and financing:
-
Thermo Fisher issued four tranches of senior unsecured notes totaling $4.8 billion:
- $1.0 billion of 4.215% notes due February 2031
- $750 million of 4.550% notes due June 2033
- $1.3 billion of 4.902% notes due February 2036
- $750 million of 5.546% notes due February 2046
-
Interest payments on the 2031, 2036, and 2046 notes will be made semi-annually on February 12 and August 12, starting August 12, 2026.
-
Interest on the 2033 notes will be paid semi-annually on June 15 and December 15, starting June 15, 2026.
-
The notes include “par call” redemption features allowing Thermo Fisher to redeem the bonds before maturity at prices tied to the present value of remaining payments plus a small premium, starting roughly five years before each maturity date.
-
After the par call dates, the company can redeem the notes at 100% of principal plus accrued interest.
-
In the event of a change of control combined with a downgrade of the notes below investment grade by at least two major rating agencies, Thermo Fisher must offer to repurchase the notes at 101% of principal plus accrued interest.
-
The notes rank equally with Thermo Fisher’s other unsecured debt and senior to any subordinated debt, but are structurally subordinated to secured debt and liabilities of subsidiaries.
-
The indenture limits Thermo Fisher’s ability to incur secured debt on key properties or engage in sale-leaseback transactions on those properties, and restricts mergers, consolidations, or asset sales without meeting certain conditions.
-
The offering was led by Deutsche Bank Securities, RBC Capital Markets, SMBC Nikko Securities America, and Wells Fargo Securities.
-
Net proceeds from the offering are expected to be approximately $3.76 billion after underwriting discounts and expenses.
-
Thermo Fisher plans to use these proceeds primarily to fund the cash portion of its previously announced acquisition of Clario Holdings, which remains subject to customary closing conditions and regulatory approvals.
-
Until the acquisition closes, the company may use the proceeds for general corporate purposes, including potential further acquisitions, debt repayment or refinancing, working capital, capital expenditures, or share repurchases.
Implications for investors:
-
This sizable debt issuance increases Thermo Fisher’s leverage but provides substantial liquidity to support its strategic acquisition of Clario, which is expected to expand its portfolio and market presence.
-
The staggered maturities and fixed interest rates reflect a balanced approach to managing interest rate risk and refinancing needs over the next two decades.
-
The covenants and redemption features offer some protections to bondholders while giving Thermo Fisher flexibility to manage its capital structure.
-
The potential use of proceeds beyond the Clario deal indicates ongoing strategic flexibility, which may include further acquisitions or capital returns to shareholders.
-
Investors should note the structural subordination of these notes to secured debt at the subsidiary level, which is typical but relevant in assessing credit risk.
Overall, this bond offering is a key financing milestone supporting Thermo Fisher’s growth strategy through acquisition, while maintaining a disciplined approach to debt management.